CRTX.LSE CRISM Therapeutics Corporation
- Market cap
- GBX 6.97M
- P/E
- -
- P/B
- 2.70x
- ROE
- -219.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CRTX.LSE undervalued?
Graham numberThe Graham number of CRISM Therapeutics Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CRISM Therapeutics Corporation fundamental analysis
No fundamental analysis for CRISM Therapeutics Corporation yet.
CRISM Therapeutics Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and consultancy services. The company was formerly known as Amur Minerals Corporation an…
Full company profileCRISM Therapeutics Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CRISM Therapeutics Corporation annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | 0.00 | 0.00 | 56.9K | 20.0K | 231K | - |
| Gross Profit | -1.82K | -6.26K | -4.75K | -4.70K | -5.30K | - | - | -3.79K | 16.8K | -117K | 370K |
| Operating Income | -3.77M | -1.92M | -2.15M | -1.56M | -3.08M | -1.79M | -2.22M | -217K | -465K | -2.11M | -6.20M |
| EBITDA | -3.43M | -2.12M | -2.15M | -1.10M | -3.08M | -1.75M | -1.95M | -195K | -449K | -2.09M | -6.16M |
| Net Income | -5.25M | -1.20M | -3.14M | -1.83M | -2.83M | -1.54M | -2.45M | -248K | -485K | -1.90M | -5.65M |
| EPS | -1.53 | -0.31 | -0.77 | -0.40 | -0.42 | -0.18 | -0.28 | -0.03 | -0.08 | -0.05 | -0.10 |
| Balance Sheet | |||||||||||
| Total Assets | 29.4M | 29.1M | 26.2M | 21.3M | 32.4M | 31.2M | 23.9M | 161K | 1.82M | 1.80M | 2.92M |
| Total Liabilities | 3.88M | 944K | 2.76M | 852K | 1.05M | 1.13M | 766K | 920K | 341K | 381K | 343K |
| Shareholders' Equity | 25.7M | 28.4M | 23.6M | 20.5M | 31.4M | 30.1M | 23.1M | 4.12M | 1.48M | 1.42M | 2.58M |
| Cash & Short-term Investments | 8.20M | 2.56M | 1.26M | 385K | 2.79M | 4.93M | 2.90M | 1.26K | 1.28M | 1.13M | 2.27M |
| Total Debt | - | - | 1.66M | - | - | - | - | 497K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.01M | -2.70M | -2.46M | -1.90M | -2.28M | -1.83M | -3.52M | -2.77M | -933K | -1.97M | -5.92M |
| Capital Expenditure | 4.12M | 3.87M | 1.95M | 393K | 440K | 426K | 265K | 12.0K | 28.0K | 31.0K | 0.00 |
| Free Cash Flow | -6.13M | -6.69M | -4.40M | -1.88M | -2.12M | -2.26M | -2.99M | -2.77M | -961K | -1.97M | -5.92M |
| Ratios | |||||||||||
| ROE | -20.4% | -4.2% | -13.3% | -8.9% | -9.0% | -5.1% | -10.6% | -6.0% | -32.9% | -134.4% | -219.2% |
| ROA | -17.8% | -4.1% | -12.0% | -8.6% | -8.7% | -4.9% | -10.2% | -154.3% | -26.7% | -105.9% | -193.4% |
| Net Profit Margin | - | - | - | - | - | - | - | -435.6% | -2,428.0% | -823.8% | - |
| Debt to Equity | - | - | 0.07x | - | - | - | - | 0.12x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CRISM Therapeutics Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 1, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | GBP 47.0K | 0.01 | - |
| 2023 | GBP 31.4M | 3.61 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:160 on May 31, 2024.
Who owns CRISM Therapeutics Corporation
- Insiders 32.47%
- Institutions 16.92%
- Public & others 50.60%
- Shares outstanding 79.7M
- Free float 79.1M
CRISM Therapeutics Corporation company profile
- Company name
- CRISM Therapeutics Corporation
- Ticker
- CRTX.LSE
- ISIN
- VGG042401262
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Kingston Chambers, Road Town, British Virgin Islands
- Website
- crismtherapeutics.com
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and consultancy services. The company was formerly known as Amur Minerals Corporation and changed its name to CRISM Therapeutics Corporation in May 2024. CRISM Therapeutics Corporation is based in Road Town, the British Virgin Islands.
CRISM Therapeutics Corporation management
3- Mr. Andrew James WebbCEO & Executive Director · born 1962
- Dr. Christopher McConvilleChief Scientific Officer & Executive Director · born 1980
- Mr. Ae Jack SwansonChief Operating Officer · born 1938